B-cell & Hematologic Antigens

Cat. No.

AT1122

Anti-GPRC5D Antibody

The Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody specifically designed to target GPRC5D, a receptor expressed predominantly on multiple myeloma cells. This antibody serves as the targeting component of the antibody-drug conjugate (ADC) LM-305, utilized in targeted cancer therapy. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This product is essential for researchers focusing on oncology and therapeutic antibody development.

Cat. No.

AT1137

Anti-CD54/ICAM-1 Antibody (R6-5-D6)

The Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a chimeric mouse monoclonal antibody of the IgG2a subclass, specifically designed to target human CD54, also known as ICAM-1. This antibody has been engineered for optimal binding specificity to ICAM-1, a critical molecule involved in inflammation and immune responses. For accurate experimental control, the recommended isotype control is Mouse IgG2a kappa, which serves as a non-reactive benchmark to help discern specific antibody interactions. This product is ideal for researchers studying cellular adhesion, immune response modulation, and ICAM-1 related pathways in various disease models.

Cat. No.

AT1138

IMMU-114

IMMU-114 is a humanized monoclonal antibody targeting human leukocyte antigen-DR (HLA-DR). This antibody is designed to deplete antigen-presenting cells (APCs) and diminish the population of alloreactive T cells, making it a valuable tool for research in immunology and transplantation studies.

Cat. No.

AT1139

CAS No.

2197112-39-1

Felzartamab

Synonyms: MOR-202

Felzartamab (MOR-202) is a human monoclonal antibody designed to specifically bind to CD38, a glycoprotein predominantly expressed on the surface of multiple myeloma cells. This antibody is utilized extensively in research focused on the pathophysiology and treatment strategies of multiple myeloma, offering a critical tool for investigating disease mechanisms and therapeutic interventions.

Cat. No.

AT1142

CAS No.

2839572-09-5

Ingitamig

Ingitamig is a bispecific antibody engineered to target TNFRSF17 and KLRK1. This dual-specificity is achieved through its (G1_L-κ)_(G1-scFvkh_L-κ) configuration, making it a versatile tool in the study of immune responses and potential therapeutic interventions.

Cat. No.

AT1150

CAS No.

1608112-78-2

Blontuvetmab

Synonyms: AT 004; VT 007

Blontuvetmab (AT 004) is a caninized monoclonal antibody targeting CD20, designed specifically for canine applications. It exhibits dual functionality by acting as a highly potent and selective antagonist of the A2aR receptor while also displaying weak agonistic activity towards the Nociceptin/Orphanin FQ receptor (NOP). This antibody effectively inhibits the activation of A2aR mediated by 5'-N-Ethylcarboxamidoadenosine (NECA), and it significantly counteracts the adenosine-induced suppression of CD8 T cell activation. This action leads to an increase in cytokine production, including IFN-γ. Blontuvetmab is primarily used in research focused on Canine B-cell lymphoma, offering a valuable tool for studying the modulation of immune responses in this condition.

Cat. No.

AT1157

CAS No.

2409099-32-5

Semzuvolimab

Synonyms: UB421

Semzuvolimab is a humanized IgG1κ monoclonal antibody specifically designed to target the p55 T cell surface antigen T4/Leu-3, commonly known as CD4. This antibody has demonstrated capabilities in neutralizing HIV infections and shows potential in inhibiting HIV infections that are stable under highly active antiretroviral therapy (HAART). Semzuvolimab offers significant utility in research focused on the immunological aspects of HIV management and therapy development.

Cat. No.

AT1176

CAS No.

214559-60-1

Bivatuzumab

Synonyms: BIWA 4; Anti-CD44 Recombinant Antibody

Bivatuzumab (BIWA 4), a humanized monoclonal antibody, targets the CD44v6 isoform, a variant of the CD44 standard form. This antibody has been specifically developed for its potential role in targeting CD44v6, which is implicated in the progression of various sarcomas. Bivatuzumab is utilized in research focusing on chimeric antigen receptor (CAR)-redirected cytokine-induced killer (CIK) cells, providing a promising therapeutic approach for sarcoma treatment.

Cat. No.

AT1195

CAS No.

2919209-65-5

Cizutamig

Synonyms: CND-106; EMB-06

Cizutamig is a dimeric humanized antibody that specifically targets TNFRSF17. It is constructed with a light chain kappa and heavy gamma 1 chain variable region, featuring a VH-G1 (CH1-h) configuration. This antibody is designed for high specificity and affinity in applications involving TNFRSF17 interaction studies.

Cat. No.

AT1237

CAS No.

1639820-81-7

Pinatuzumab

Pinatuzumab is a monoclonal antibody specifically targeting the cell-surface antigen CD22. This antibody is employed primarily in the development of antibody-drug conjugates (ADCs) for the investigation of various diseases, notably non-Hodgkin lymphoma (NHL). Pinatuzumab's specificity for CD22 makes it a valuable tool in research focused on hematological malignancies.

Cat. No.

AT1272

CAS No.

899796-83-9

Milatuzumab

Synonyms: hLL1; MEDI-115

Milatuzumab (hLL1; MEDI-115) is a humanized monoclonal antibody targeting CD74, an integral membrane protein implicated in the promotion of B-cell growth and survival. This antibody induces the generation of reactive oxygen species and disrupts mitochondrial membrane potential, leading to apoptosis. Additionally, Milatuzumab reduces CD20/CD74 aggregates and cell adhesion, further promoting cell death. This antibody is pivotal for research into the mechanisms of B-cell malignancies and autoimmune diseases, where CD74 plays a key role.

Cat. No.

AT1307

CAS No.

2251143-19-6

Zuberitamab

Synonyms: HS006

Zuberitamab (HS006) is a monoclonal antibody specifically designed to target CD20, a cell surface protein predominantly expressed on B cells. This antibody is utilized extensively in the study of various B-cell malignancies, including diffuse large B-cell lymphoma. Zuberitamab serves as a critical tool in oncological research, aiding in the elucidation of CD20's role in cancer pathogenesis and the development of targeted therapies.

Cat. No.

AT1313

CAS No.

1608122-71-9

Tamtuvetmab

Synonyms: AT-005

Tamtuvetmab (AT-005) is a caninized version of blontuvetmab targeting CD52, designed specifically for veterinary use. This therapeutic antibody has demonstrated an ability to increase progression-free survival (PFS) and shows in vivo efficacy in canine subjects with naive T-cell lymphoma (LSA). Tamtuvetmab has received approval for veterinary applications, underscoring its relevance and utility in the treatment of lymphoma in dogs.

Cat. No.

AT1321

CAS No.

1207446-68-1

Tregalizumab

Synonyms: BT-061

Tregalizumab is a humanized IgG1 monoclonal antibody targeting the CD4 antigen. It selectively enhances the suppressive function of regulatory T cells (Tregs) in vitro, making it a valuable tool for studying autoimmune disorders and allergies where Treg activity is compromised. This antibody's specificity and mechanism of action provide a critical resource for investigating the pathophysiology of immune tolerance and its therapeutic modulation.

Cat. No.

AT1326

CAS No.

1143503-67-6

Tabalumab

Synonyms: LY2127399

Tabalumab (LY2127399) is a human monoclonal antibody of the IgG4 subtype designed to specifically target and neutralize both membrane-bound and soluble forms of B-cell activating factor (BAFF). This antibody exhibits potent neutralizing activity, making it a valuable tool for research into autoimmune disorders including rheumatoid arthritis, renal failure, and systemic lupus erythematosus. Tabalumab's specificity and efficacy in modulating BAFF-mediated processes provide a critical resource for investigating the pathophysiology and potential therapeutic interventions for these conditions.

Cat. No.

AT1332

CAS No.

949142-50-1

Obinutuzumab

Synonyms: GA101; Anti-Human CD20 type II; Humanized Antibody

Obinutuzumab (GA101) is a humanized IgG1 monoclonal antibody of Type II targeting CD20, currently under development for the treatment of non-Hodgkin lymphoma. This therapeutic antibody is designed to bind specifically to the CD20 antigen expressed on the surface of B cells, facilitating targeted immunotherapy with potential applications in oncological research and clinical practice.

Cat. No.

AT1338

CAS No.

174722-30-6

Keliximab

Synonyms: SB-210396; IDEC CE9.1

Keliximab (SB-210396) is a chimeric human/macaque IgG1 monoclonal antibody targeting CD4 with a dissociation constant (Ki) of 1.0 nM for soluble CD4. This antibody effectively blocks T-cell proliferation and inhibits the production of interleukin-2 (IL-2), mechanisms critical in the immune response. Due to its specific action on T-cells, Keliximab is extensively utilized in oncological research to study the modulation of the immune system in the tumor microenvironment.

Cat. No.

AT1343

CAS No.

1875032-68-0

Loncastuximab

Synonyms: RB4v1.2

Loncastuximab (RB4v1.2) is a monoclonal antibody targeting CD19, demonstrating significant antitumor activity. This antibody is primarily utilized in the investigation of hematological malignancies, including Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Its specificity for CD19 makes it a valuable tool for researchers studying the pathophysiology and potential therapeutic interventions for these conditions.

Cat. No.

AT1361

Anti-CD25/IL-2Rα Antibody (7G7B6)

The Anti-CD25/IL-2Rα Antibody (7G7B6) is a chimeric monoclonal antibody derived from mouse IgG2a, specifically designed to target human CD25/IL-2Rα. This antibody is ideal for investigating the role of CD25/IL-2Rα in immune regulation and has applications in various immunological assays. For accurate experimental control, it is recommended to use Mouse IgG2a kappa as the isotype control.

Cat. No.

AT1377

CAS No.

2227490-52-8

Mezagitamab

Synonyms: TAK-079

Mezagitamab (TAK-079) is an IgG1λ monoclonal antibody targeting CD38. This antibody facilitates the depletion of tumor cells that express CD38 via mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It is currently being investigated for its therapeutic potential in treating conditions such as relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP), demonstrating significant relevance in clinical research settings focused on hematologic malignancies and autoimmune disorders.

Cat. No.

AT1424

CAS No.

1826819-58-2

Azintuxizumab vedotin

Synonyms: ABBV-838

Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) specifically designed to target a unique epitope of CD2 subset 1, a cell-surface glycoprotein prevalently expressed on multiple myeloma cells. This targeted approach allows for the direct delivery of cytotoxic agents to the cancer cells, potentially enhancing therapeutic efficacy while minimizing off-target effects. Azintuxizumab vedotin is primarily utilized in research focused on the treatment and understanding of multiple myeloma.

Cat. No.

AT1439

CAS No.

2720478-38-4

Budoprutug

Budoprutug is a human IgG1 κ monoclonal antibody targeting CD19. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Cat. No.

AT1468

CAS No.

2382896-07-1

Sibeprenlimab

Synonyms: VIS649

Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody designed to inhibit the activity of a proliferation-inducing ligand (APRIL). This antibody selectively suppresses pathogenic immunoglobulins, specifically IgA and IgM, while maintaining effective antibody responses to mRNA-based SARS-CoV-2 vaccines. Additionally, Sibeprenlimab has demonstrated potential in reducing the urinary protein-to-creatinine ratio (UPCR) and stabilizing glomerular filtration rate (GFR), indicating its utility in the investigation of IgA nephropathy (IgAN). This makes Sibeprenlimab a valuable tool for research focused on autoimmune renal disorders and immune response modulation.

Cat. No.

AT1477

CAS No.

2925692-65-3

Pamlectabart

Pamlectabart is a humanized IgG1κ antibody that specifically targets TNFRSF17. For experimental consistency and control, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT1486

CAS No.

945721-28-8

Daratumumab

Synonyms: Anti-Human CD38; Human Antibody

Daratumumab is a pioneering human-specific monoclonal antibody (IgG1) targeting CD38, a surface antigen widely expressed on multiple myeloma (MM) cells. This first-in-class antibody exhibits potent anti-myeloma activity by disrupting cell adhesion, thereby enhancing the susceptibility of MM cells to proteasome inhibitors. Daratumumab serves as a critical tool in the therapeutic arsenal against multiple myeloma, offering a novel mechanism of action that complements existing treatment modalities.